Cargando…

Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma

Medulloblastoma (MB), grouped as either WNT-activated, Sonic hedgehog (SHH)-activated, or non-WNT/non-SHH group 3, accounts for almost 20% of all childhood brain cancers. In spite of current intensive treatments, not all patients are cured and survivors suffer from severe side-effects. The present s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukoseviciute, Monika, Theodosopoulou, Aikaterini, Holzhauser, Stefan, Dalianis, Tina, Kostopoulou, Ourania N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196712/ https://www.ncbi.nlm.nih.gov/pubmed/37144508 http://dx.doi.org/10.3892/or.2023.8562

Ejemplares similares

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines
por: Lukoseviciute, Monika, et al.
Publicado: (2023)

Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited
por: Byskata, Karin, et al.
Publicado: (2022)

Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors
por: Kostopoulou, Ourania N., et al.
Publicado: (2022)

Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines
por: Lukoseviciute, Monika, et al.
Publicado: (2021)

Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines
por: Holzhauser, Stefan, et al.
Publicado: (2021)

Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations
por: Holzhauser, Stefan, et al.
Publicado: (2021)

Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma
por: Näsman, Anders, et al.
Publicado: (2021)

The transcriptional landscape of Shh medulloblastoma
por: Skowron, Patryk, et al.
Publicado: (2021)

Drug Delivery Systems for Hedgehog Inhibitors in the Treatment of SHH-Medulloblastoma
por: Caimano, Miriam, et al.
Publicado: (2021)

Evasion of cell senescence in SHH medulloblastoma
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2016)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

EPCT-17. DEVELOPING EYA PHOSPHATASE INHIBITORS WITH ON-TARGET EFFECTS IN SHH-MEDULLOBLASTOMA
por: H. Hwang, Grace, et al.
Publicado: (2021)

High Levels of FGF11 Correlate with Poor Survival in Patients with Human Papillomavirus (HPV)-Positive Oropharyngeal Squamous Cell Carcinoma
por: de Flon, Caroline Haglund, et al.
Publicado: (2023)

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
por: Remke, Marc, et al.
Publicado: (2013)

Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas
por: Lee, Chanhee, et al.
Publicado: (2018)

Disruption of rack1 suppresses SHH‐type medulloblastoma formation in mice
por: Liu, Fengjiao, et al.
Publicado: (2021)

BIOL-08. IGFBP2 PROMOTES TUMOR METASTASIS IN SHH MEDULLOBLASTOMA
por: Kunhiraman, Haritha, et al.
Publicado: (2021)

EMBR-19. SHH-DRIVEN MEDULLOBLASTOMA WITH CONCURRENT UNILATERAL RENAL AGENESIS
por: Aaroe, Ashley, et al.
Publicado: (2021)

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression
por: Wynn, Daniel T, et al.
Publicado: (2022)

An ABC transporter as a potential target against SHH-Medulloblastoma: From Benchtop to Bedside
por: Zhu, Jingwen, et al.
Publicado: (2022)

Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression
por: Zagozewski, Jamie, et al.
Publicado: (2022)

MBRS-51. MUTATIONS IN BRPF1 FOUND IN SHH MEDULLOBLASTOMA PREVENT INTERACTION WITH TP53 AND LEADS TO RADIORESISTANCE IN VITRO
por: Vouri, Mikaela, et al.
Publicado: (2020)

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2019)

Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma
por: Łastowska, Maria, et al.
Publicado: (2019)

Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma
por: Azzollini, Jacopo, et al.
Publicado: (2020)

Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma
por: Neve, Anuja, et al.
Publicado: (2019)

Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2019)

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
por: Ghasemi, David R., et al.
Publicado: (2022)

EMBR-33. YAP1 FUNCTION IN SHH MEDULLOBLASTOMA PROGRESSION AND IMMUNE EVASION
por: Abdelfattah, Nourhan, et al.
Publicado: (2021)

MEDB-48. Infant medulloblastoma - SHH subtype – with residual disease. To treat or not to treat
por: Dahl, Christine, et al.
Publicado: (2022)

MEDB-66. Investigating intra-tumoral heterogeneity of extrachromosomal DNA in SHH medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)

Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors
por: Moss, Rachel M., et al.
Publicado: (2023)

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality
por: Dang, Mai T., et al.
Publicado: (2021)

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality
por: Dang, Mai T., et al.
Publicado: (2023)

Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours
por: Łastowska, Maria, et al.
Publicado: (2015)

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
por: Zhang, Zhen-Yu, et al.
Publicado: (2014)

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
por: Kresbach, Catena, et al.
Publicado: (2022)

MEDB-22. iPSC-derived cerebellar organoid model for hereditary genetic predisposition in SHH-medulloblastoma
por: Manz, Frederik, et al.
Publicado: (2022)

Correction: Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2jli6cvmukd5vrbdr22rftn4he